Danone Leads the Charge in Precision Fermentation Innovation
Precision fermentation, a revolutionary technology in food production, is garnering increasing attention for its ability to develop flavors, vitamins, plant-based proteins, and other specialty ingredients with greater precision than traditional methods.
Danone, a major player in the dairy industry, is actively involved in this burgeoning field. The company is not only building infrastructure to support start-ups in scaling precision fermentation but is also conducting its own research in the area. This exploration is taking place at Danone's innovation center in Paris-Saclay, France, where novel technologies are being studied to enhance the global food system.
Emmanuel Perrin, senior director of advanced technology ingredients at Danone, emphasizes the importance of precision fermentation in addressing the strain on the global protein supply. Rather than replacing animal protein, precision fermentation can develop complementary animal-free proteins, crucial as the world's population continues to swell.
Perrin acknowledges that precision fermentation is currently in an exploratory phase for Danone, citing challenges in scalability, regulatory approval, and consumer demand. However, he remains optimistic about its potential, noting that consumers are increasingly seeking health-conscious food options.
A significant asset in Danone's research efforts is their vast library of ferments, housing 1,900 strains. Described as "a bit of a treasure" by Perrin, these ferments are integral to the company's product development, including the creation of Activia, and are vital to their precision fermentation research.
Danone's collaboration with start-ups extends beyond research. In partnership with Michelin, DMC Technologies, and Crédit Agricole, they are constructing a production facility to enable start-ups to overcome the "valley of death" by offering scalability in precision fermentation production.
The advent of precision fermentation is further propelled by advancements in CRISPR-Cas9 gene editing technology and AI, enhancing the efficiency of microorganisms involved in the process. While scaling remains a challenge, ongoing research is making strides towards more cost-effective solutions at the proof of concept stage.
